Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.
Bibliographic record
Abstract
8611 Background: PDL1V is an investigational antibody-drug conjugate that delivers the cytotoxic agent monomethyl auristatin E to cells expressing programmed cell death ligand 1 (PD-L1). In addition to cytotoxicity, PDL1V elicits antitumor activity via the bystander effect and immunogenic cell death. Here we present the safety profile and preliminary efficacy in patients with metastatic, relapsed/refractory non-small cell lung cancer (NSCLC) enrolled in the phase 1 trial. Methods: C5851001 (NCT05208762) is a phase 1 study enrolling patients with relapsed or refractory solid tumors, including NSCLC, whose disease has progressed on standard-of-care therapies. Patients received the PDL1V recommended expansion dose of 1.5 mg/kg on days 1 and 8 of a 21-day cycle using adjusted ideal body weight, and were required to have measurable disease per RECIST v1.1 and ECOG PS ≤1. Patients with genomic alterations were not excluded. The primary objectives of this study are safety, tolerability, and pharmacokinetics, with antitumor activity as a secondary objective. Results: As of December 20, 2024, 30 patients with NSCLC have been treated at the recommended expansion dose. The median age was 60 years (range 44-73); 43.3% were male, 66.7% had ECOG PS 1, 23.3% had squamous histology, and 83.3% were PD-L1 positive. The median number of prior lines of therapy was 2.0 (1, 8); 96.7% and 66.7% of patients were previously exposed to anti-PD-1/PD-L1 antibodies and taxanes, respectively. There have been no dose-limiting toxicities at the recommended expansion dose. Peripheral sensory neuropathy (27.2%), nausea (25.0%), diarrhea (23.9%), and fatigue (21.7%) were the most common treatment-related adverse events (TRAEs) for all patients treated in the Phase 1 trial at the recommended expansion dose (N=92); the majority of TRAEs were grade 1-2 in severity, and 5.4% of patients discontinued therapy due to TRAEs. The most common grade ≥3 TRAE was anemia (5.4%). The incidence of treatment-related immune-mediated AEs by investigator assessment was 14.1%; 5.4% for grade 3, with no grades 4 or 5. The investigator-assessed confirmed objective response rate (cORR) for patients with NSCLC was 26.7%, while the cORR was 32.0% for those with PD-L1 expressing tumors. The median duration of confirmed response was 7.8 months (95% CI 4.8, –), and the median follow-up was 10.0 months (95% CI 4.9, 13.1). Objective responses were observed in patients with PD-L1 expressing squamous (n=6) and non-squamous (n=19) tumors (33.3% and 31.6% cORR, respectively). Conclusions: PDL1V monotherapy at the recommended expansion dose was generally well tolerated with a manageable safety profile. Encouraging preliminary efficacy in NSCLC was observed, independent of histology. Based on these results, further development of PDL1V in NSCLC is ongoing. Clinical trial information: NCT05208762 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".